Germline PALB2 pathogenic variant — BRCA2's recruitment partner; biallelic LOF produces a...
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | RF-PAN-PALB2-PARPI-CANDIDATE |
|---|---|
| Тип | Тривожна ознака |
| Статус | переглянуто 2026-04-29 | очікує клінічного підпису |
| Хвороби | DIS-BREAST DIS-PDAC DIS-PROSTATE |
| Джерела | SRC-NCCN-BREAST-2025 SRC-NCCN-PANCREATIC-2025 SRC-NCCN-PROSTATE-2025 SRC-PROFOUND-DEBONO-2020 |
Походження тривожної ознаки
| Визначення | Germline PALB2 pathogenic variant — BRCA2's recruitment partner; biallelic LOF produces an HRR-deficient phenotype. Pan-tumor PARPi candidate signal weaker than gBRCA1/2 but emerging. Disease applicability: breast (lifetime risk ~35-55%, NCCN high-penetrance — PARPi off-label / investigational), PDAC (~3-5x baseline risk, POLO label is gBRCA-only but PALB2 frequently grouped clinically), prostate mCRPC (cohort-B in PROfound HRR-non-BRCA/ATM — smaller absolute olaparib benefit but PARPi remains an option per NCCN 2025). Genetic counseling + cascade testing of first-degree relatives required. |
|---|---|
| Клінічний напрям | intensify |
| Категорія | high-risk-biology |
Логіка спрацьовування
{
"any_of": [
{
"finding": "palb2_germline",
"value": "pathogenic"
},
{
"finding": "palb2_status",
"value": "pathogenic"
},
{
"finding": "germline_palb2",
"value": "pathogenic"
},
{
"finding": "palb2_pathogenic",
"value": true
}
],
"type": "biomarker"
}
Нотатки
References BIO-PALB2-GERMLINE. Surveillance recommendations: enhanced breast screening (annual MRI from age 30), pancreatic surveillance per CAPS consortium when family history present. RF distinct from RF-BREAST-BRCA-GERMLINE-ACTIONABLE (BRCA-specific) and RF-PROSTATE-HIGH-RISK-BIOLOGY (which captures HRR pathway broadly via hrr_pathway_mutation key but does not key on palb2_germline directly). No NCCN hereditary-cancer panel source exists in KB — using disease-specific NCCN sources instead; flagged in commit body.
Де використовується
Indications
IND-PROSTATE-MCRPC-2L-CABAZITAXEL- IND-PROSTATE-MCRPC-2L-CABAZITAXELIND-PROSTATE-MCRPC-2L-DOCETAXEL- IND-PROSTATE-MCRPC-2L-DOCETAXEL